Update on Ebola virus and its potential as a bioterrorism agent

Clinical Pulmonary Medicine

Volumn 12, Issue 2, 2005, Pages 76-83

  Kagan, Elliott ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

Author keywords

Bioterrorism agent; Disseminated intravascular coagulopathy; Ebola hemorrhagic fever; Review article; Vaccines

Indexed keywords

3 DEAZANEPLANOCIN A; ADENOSINE DERIVATIVE; ADENOVIRUS VECTOR; ANTICOAGULANT AGENT; CYANOVIRIN N; DNA VACCINE; GLYCOPROTEIN; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN G1 ANTIBODY; KZ 52; NUCLEOSIDE DERIVATIVE; PROTEIN VP24; PROTEIN VP30; PROTEIN VP35; PROTEIN VP40; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN; RECOMBINANT PROTEIN; RIBAVIRIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

APOPTOSIS; BIOLOGICAL WARFARE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DENDRITIC CELL; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA VIRUS; EPIDEMIC; HUMAN; IMMUNIZATION; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG EDEMA; LUNG INFECTION; LYMPHOCYTE; MACROPHAGE; MONOCYTE; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTEIN EXPRESSION; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RNA VIRUS; UPREGULATION; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS PARTICLE;

EID: 14944379144     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000156700.53793.c5     Document Type: Review

References (86)

1. Sanchez A, Khan AS, Zaki SR et al. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Griffin DE, et al, eds. Fields Virology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1279-1304.
2. Sanchez A, Kiley MP, Holloway BP, et al. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 1993;29:215-240.
3. Sanchez A, Trappier SG, Mahy BW, et al. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A. 1996;93:3602-3607.
4. Sanchez A, Yang ZY, Xu L, et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol. 1998;72:6442-6447.
5. Mühlberger E, Weik M, Volchkov VE, et al. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol. 1999;73:2333-2342.
6. Feldmann H, Volchkov VE, Volchkova VA, et al. Biosynthesis and role of filoviral glycoproteins. J Gen Virol. 2001;82:2839-2848.
7. Feldmann H, Jones S, Klenk HD, et al. Ebola virus: from discovery to vaccine. Nat Rev Immunol. 2003;3:677-685.
8. Feldmann H, Klenk HD. Marburg and Ebola viruses. Adv Virus Res. 1996;47:1-52.
9. Noda T, Sagara H, Suzuki E, et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol. 2002;76:4855-4865.
10. Harty RN, Brown ME, Wang G, et al. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A. 2000;97:13871-13876.
11. Kissling RE, Robinson RQ, Murphy FA, et al. Agent of disease contracted from green monkeys. Science. 1968;160:888-890.
12. Gear JS, Cassel GA, Gear AJ, et al. Outbreak of Marburg virus disease in Johannesburg. BMJ. 1975;4:489-493.
13. Bowen ET, Lloyd G, Harris WJ, et al. Viral haemorrhagic fever in southern Sudan and northern Zaire: preliminary studies on the aetiological agent. Lancet. 1977;1:571-573.
14. Ebola haemorrhagic fever in Sudan, 1976: report of a WHO/International Study Team. Bull World Health Organ 1978;56:247-270.
15. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ. 1983;61:997-1003.
16. Heymann DL, Weisfeld JS, Webb PA, et al. Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978. J Infect Dis. 1980;142:372-376.
17. Jahrling PB, Geisbert TW, Dalgard DW, et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet. 1990;335:502-505.
18. Outbreak of Ebola viral hemorrhagic fever: Zaire, 1995. MMWR Morb Mortal Wkly Rep. 1995;44:381-382.
19. Le Guenno B, Formentry P, Wyers M, et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet. 1995;345:1271-1274.
20. Sanchez A, Ksiazek TG, Rollin PE, et al. Reemergence of Ebola virus in Africa. Emerg Infect Dis. 1995;1:96-97.
21. Khan AS, Tshioko FK, Heymann DL, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179(suppl 1):S76-S86.
22. Miranda ME, Ksiazek TG, Retuya TJ, et al. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis. 1999; 179(suppl 1):S115-S119.
23. Dowell SF, Mukunu R, Ksiazek TG, et al. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995: Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179(suppl 1):S87-S91.
24. Bennett D, Brown D. Ebola virus. BMJ. 1995;310:1344-1345.
25. Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999;179(suppl 1):S1-S7.
26. Sureau PH. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev Infect Dis. 1989;11(suppl 4):S790-S793.
27. Ellis DS, Simpson IH, Francis DP, et al. Ultrastructure of Ebola virus particles in human liver. J Clin Pathol. 1978;31:201-208.
28. Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res. 1995;39:129-150.
29. Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Topics Microbiol Immunol. 1999;235:97-116.
30. Villinger F, Rollin PE, Brar SS, et al. Markedly elevated levels of interferon (IFN)-g, IFN-a, interleukin (IL)-2, IL-10, and tumor necrosis factor-a associated with fatal Ebola virus infection. J Infect Dis. 1999; 179(suppl 1):S188-S191.
31. Hensley LE, Young HA, Jahrling PB, et al. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett. 2002;80: 169-179.
32. Baskerville A, Fisher-Hoch SP, Neild GH, et al. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol. 1985;147:199-209.
33. Johnson E, Jaax N, White J, et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol. 1995;76:227-236.
34. Baize S, Leroy EM, Georges-Courbot M-C, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5:423-426.
35. Geisbert TW, Hensley LE, Gibb TR, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000;80:171-186.
36. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol. 2003; 163:2347-2370.
37. Eitzen EM. Use of biological weapons. In: Sidell FR, Takafuji ET, Franz DR, eds. Medical Aspects of Chemical and Biological Warfare, Textbook of Military Medicine, Part I: Warfare, Weaponry, and the Casualty. Washington, DC: Office of the Surgeon General at TMM Publications; 1997:437-450.
38. Jahrling PB. Viral hemorrhagic fevers. In: Sidell FR, Takafuji ET, Franz DR, eds. Medical Aspects of Chemical and Biological Warfare, Textbook of Military Medicine, Part 1: Warfare. Weaponry, and the Casualty. Washington, DC: Office of the Surgeon General at TMM Publications; 1997:591-602.
39. Davis CJ. Nuclear blindness: an overview of the biological weapons programs of the former Soviet Union and Iraq. Emerg Inject Dis. 1999;5:509-512.
40. Kortepeter MG, Parker GW. Potential biological weapons threats. Emerg Infect Dis. 1999;5:523-527.
41. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287:2391-2405.
42. Chepurnov AA, Chuev Iu P, P'Iankov OV, et al. The effect of some physical and chemical factors on inactivation of the Ebola virus [in Russian]. Vopr Virusol. 1995;40:74-76.
43. Gibb TR, Norwood DA Jr, Woollen N, et al. Viral replication and host gene expression in alveolar macrophages infected with Ebola virus (Zaire strain). Clin Diagn Lab Immunol. 2002;9:19-27.
44. Kagan E, Geisbert TW, Li Y, et al. Ebola virus Zaire subtype can replicate and induce the formation of reactive nitrogen species in human bronchial epithelial cells. Am J Respir Crit Care Med. 2003:A435.
45. Medina MF, Kobinger GP, Rux J, et al. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther. 2003;8:777-789.
46. Jaax N, Jahrling P, Geisbert T, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet. 1995;346:1669-1671.
47. P'Iankov OV, Sergeev AN, P'Iankova OG, et al. Experimental Ebola fever in Macaco mulatta [in Russian]. Vopr Virusol. 1995;40:113-115.
48. Bazhutin NB, Belanov EF, Spiridonov VA, et al. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys [in Russian]). Vopr Virusol. 1992;37:153-156.
49. Ryabchikova E, Kolesnikova L, Smolina M, et al. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol. 1996;141:909-921.
50. Chepurnov AA, Dadaeva AA, Zhukov VA, et al. Change in biochemical and hemostatic indicators in guinea pigs upon administering Ebola virus preparations [in Russian]. Vopr Virusol. 1997;42:171-175.
51. Bray M, Davis K, Geisbert T, et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis. 1998;178:651-661.
52. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis. 1999;179(suppl 1):S203-S217.
53. Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8:503-507.
54. Geisbert TW, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev Vaccines. 2003;2:89-101.
55. Bray M, Hatfill S, Hensley L, et al. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol. 2001;125:243-253.
56. Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188:1618-1629.
57. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163:2371-2382.
58. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95:930-935.
59. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol. 2002;128:163-168.
60. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002;300:729-735.
61. Feldmann H, Bugany H, Mahner F, et al. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol. 1996; 70:2208-2214.
62. Choe N, Tanaka S, Kagan E. Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am J Respir Cell Mol Biol. 1998;19:226-236.
63. Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis. 2003;188:1613-1617.
64. Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355:2210-2215.
65. Mahanty S, Hutchinson K, Agarwal S, et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol. 2003;170:2797-2801.
66. Bosio CM, Aman MJ, Grogan C, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis. 2003;188:1630-1638.
67. Daniel PT, Scholz C, Westermann J, et al. Dendritic cells prevent CD95 mediated T lymphocyte death through costimulatory signals. Adv Exp Med Biol. 1998;451:173-177.
68. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411.
69. Charrel RN, de Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res. 2003;57:89-100.
70. Brinton MA, Gavin EI, Lo WK, et al. Characterization of murine Caraparu bunyavirus liver infection and immunomodulator-mediated antiviral protection. Antiviral Res. 1993;20:155-171.
71. Bray M, Raymond JL, Geisbert T, et al. 3-Deazaneplanocin A induces massively increased interferon-a production in Ebola virus-infected mice. Antiviral Res. 2002;55:151-159.
72. Barrientos LG, O'Keefe BR, Bray M, et al. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003;58:47-56.
73. Vlasuk GP, Rote WE. Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. Trends Cardiovasc Med. 2002;12:325-331.
74. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001;104:74-78.
75. Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol. 2003;41:2147-2153.
76. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients: International Scientific and Technical Committee. J Infect Dis. 1999;179(suppl 1):S18-S23.
77. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-a2b for treatment of experimental Ebola virus infections. J Infect Dis. 1999;179(suppl 1):S224-S234.
78. Enserink M. Virology: new vaccine and treatment excite Ebola researchers. Science. 2003;302:1141-1142.
79. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998;246:134-144.
80. Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med. 1998;4:37-42.
81. Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000;19:142-153.
82. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424:681-684.
83. Wilson JA, Bray M, Bakken R, et al. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology. 2001;286:384-390.
84. Takada A, Feldmann H, Stroeher U, et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol. 2003;77:1069-1074.
85. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A. 2003;100:15889-15894.
86. Vastag B. Ebola vaccines tested in humans, monkeys. JAMA. 2004;291: 549-550.